New drug karonudib tested in blood cancer patients

NCT ID NCT04077307

Recruiting now Disease control Sponsor: Thomas Helleday Foundation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonudib will be effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: karonudib
What this could lead to: If successful, this could point toward a new treatment option for people with blood cancers who have run out of standard therapies.
What could go wrong: This is a very early, small trial with only 9 people, focused on safety. It may not show any benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell neoplasm Burkitt lymphoma diffuse large B-cell lymphoma leukemia myelodysplastic syndrome plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA

Contacts and locations

Locations

Aarhus University Hospital
RECRUITING

Aarhus, Denmark
Karolinska University Hospital
RECRUITING

Huddinge, Sweden
Rigshospitalet Copenhagen University Hospital
RECRUITING

Copenhagen, Denmark
University Clinical Center Belgrade
RECRUITING

Belgrade, Serbia
University Clinical Center Kragujevac
RECRUITING

Kragujevac, Serbia
Vojnomedicinska akademija, Klinika za hematologiju
RECRUITING

Belgrade, Serbia
Örebro University Hospital
RECRUITING

Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.